+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
World Market for Oncology Imaging AI, 2023-2032- Product Image
World Market for Oncology Imaging AI, 2023-2032- Product Image
New

World Market for Oncology Imaging AI, 2023-2032

  • PDF Icon

    Report

  • 643 Pages
  • December 2025
  • Region: Global
  • Marketstrat Inc
  • ID: 6212486
Description Jump to:

Oncology is where medical imaging AI is being tested most aggressively - and where it is starting to stick. Breast and lung screening programs, complex CT/MRI staging, PET-based theranostics, and RT planning are all pushing clinicians toward faster, more consistent, more quantitative imaging decisions.

This report quantifies and explains that shift. It analyzes the World Market for Oncology Imaging AI from 2023 to 2032, using a consistent segmentation across:

  • Modality: CT, X-ray/DR (incl. DBT), MRI, PET/Nuclear, Ultrasound
  • Tumor site: Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-oncology, and others
  • Clinical application & pathway stage: from Screening & Risk through Treatment Planning and Response
  • Revenue stream & buyer type: Hardware attach, Software, Services, Cloud/PPU across Cancer Centers, IDNs/AMCs, Community providers, and Teleradiology

Beyond the numbers, the report applies the full framework stack - M³, ARC-Index, GTM Growth-Maturity, and the new Upgrade & Package Ladders - to show how AI Software vendors, Imaging OEMs, RT planning providers, AI Platforms, Providers/Telerad networks, and Imaging-Pharma/CROs can convert opportunity into repeatable, profitable business.

The goal is not just to describe the market, but to give executives an insights-to-action playbook: where Oncology Imaging AI is truly ready to scale, which clusters will capture the value, and what evidence, packaging, and partnerships will matter most over the next three to five years.

Market Snapshot

Oncology Imaging AI has moved from experimental pilots to a fast scaling market. The report sizes a global opportunity that expands more than 10x between 2023 and 2032, with a compound annual growth rate in the low 30s. North America remains the largest revenue pool over the horizon, but Asia-Pacific is the fastest growing region, overtaking Europe on momentum as national breast and lung programs, domestic OEMs, and cloud first deployments ramp. Europe stays a strong second engine, with adoption paced by MDR, HTA, and national screening strategies.

Most spend concentrates in CT, X ray/DBT and MRI oncology workflows, with PET/Nuclear and Ultrasound forming smaller but high value niches tied to theranostics, quantification, and interventional oncology. The mix of value pools also shifts along the pathway: Detection & Diagnosis remains foundational, but more spend migrates toward screening, treatment planning, and response assessment, where lesion level segmentation, dosimetry, and structured reporting are becoming mandatory for modern cancer programs.

The report quantifies Oncology Imaging AI across regions and countries, modalities, tumor sites, clinical applications, pathway stages, revenue streams, and end use settings (cancer centers, IDNs/AMCs, community providers, teleradiology). Detailed numbers are reserved for report buyers; the public snapshot is directional by design.

What’s Covered

  • Global market sizing & forecast (2023-2032): total Oncology Imaging AI market today and through 2032, with growth outlook, scenario commentary and key inflection points along the decade.
  • Granular segmentation of value pools: analysis by modality, tumor site, clinical application, pathway stage, revenue stream and end-use setting (cancer centers, IDNs/AMCs, community hospitals, imaging centers, teleradiology), aligned with the broader AI-in-Imaging taxonomy.
  • Regional & country perspectives: detailed views for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, including commentary on leading and fast-growth countries, screening initiatives, and local regulatory/reimbursement dynamics.
  • Clinical & technology trends across the oncology pathway: how AI is being deployed from breast and lung screening through CT/MR staging, RT planning, PET theranostics and longitudinal response assessment, with use-case mapping to Screening, Diagnosis, Staging, Planning, Response and Surveillance stages.
  • Regulatory, reimbursement and evidence landscape (ARC): assessment of Approvals, Reimbursement and Clinical validation by key use case (e.g., DBT AI, CT-lung, adaptive RT, PET response, radiomics), including where Oncology Imaging AI is deployment-ready vs where it remains pilot-only.
  • Competitive landscape by cluster: analysis of six major competitive clusters (AI Software, Imaging OEMs, RT/TPS vendors, AI Platforms & Cloud, Providers & Teleradiology, Imaging-Pharma/CRO & Trials), with GTM Growth-Maturity positioning and qualitative company spotlights.
  • GTM & packaging strategies: Upgrade & Package Ladders for each cluster (Foundation / Advanced / Elite), recommended commercial and pricing rules, channel and partnership strategies, and implications for attach-rate expansion and suite-based selling.
  • Strategic implications & scenarios: cross-cutting insights on where Oncology Imaging AI is likely to become “workflow-critical infrastructure,” how APAC’s faster growth changes global competition, and what boards, product leaders and investors should prioritize over the next 3-5 years.

Companies Covered

5C Network; Accuray; Aidoc; AIQ Solutions; Bracco; Brainlab; Canon Medical; CARPL.ai; deepc (deepcOS); DocPanel; Elekta; Everlight Radiology; Ferrum Health; Fujifilm Healthcare; GE HealthCare; Guerbet; Hologic; Incepto; Koios Medical; Lantheus / EXINI (aPROMISE / PYLARIFY AI); Limbus AI; Lunit; Median Technologies; MIM Software; Mirada Medical; MVision AI; Nuance Precision Imaging Network (PIN); Philips Healthcare; Quibim; QView Medical; RadNet / DeepHealth; RaySearch Laboratories; Riverain Technologies; Samsung Healthcare; ScreenPoint Medical (Transpara); Siemens Healthineers; Teleradiology Solutions; Tempus (Arterys); Therapixel (MammoScreen); Unilabs / Telemedicine Clinic (TMC); United Imaging; Vara; vRad.

The list is cluster balanced - it includes AI software specialists, modality OEMs, RT/TPS vendors, platform players, provider/telerad networks, and imaging pharma/iCROs that feature in the oncology analysis.

Geographical Coverage

  • North America (US, Canada)
  • Europe (Germany, France, UK, Italy, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia-Pacific)
  • Latin America
  • Middle East & Africa

Market Segmentation

  • By Modality (CT, X-ray/DR. MRI, PET/Nuclear, Ultrasound)
  • By Geographic Region (see above for Geographic Coverage)
  • By Tumor Site (Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-Onc, Gyn, H&N, Other)
  • By Clinical Application (Detection/Triage, Seg/Quant, Reporting/NLP, Recon/Dose, Workflow Orchestration)
  • By Pathway Stage (Screening, Diagnosis, Staging, Planning (RT), Therapy Response, Surveillance
  • By End-Use Org (Cancer Centers, IDNs/AMCs, Community Hospitals, Imaging Centers, Teleradiology)
  • By Revenue Stream (Hardware Uplift, Software Licenses, Services, Cloud/PPU)
  • By AI Technology (Detection, Seg/Quant, Radiomics, NLP/LLM, Governance)

Key Topics Covered

  • Global market sizing & forecast (2023-2032)
  • Granular segmentation of value pools
  • Regional & country perspectives
  • Clinical & technology trends across the oncology pathway
  • Regulatory, reimbursement and evidence landscape (ARC)
  • Competitive landscape by cluster
  • GTM & packaging strategies
  • Strategic implications & scenarios

Methodology

  • Horizon Research Program - Medical Imaging & AI

Table of Contents

Section 1 Executive Summary
  • Why This Market Matters
  • Global Growth at a Glance
  • Where Along the Pathway the Money Is Moving
  • Global Market Drivers and Restraints
  • Key Growth Drivers
  • Structural Restraints
  • Regional Pulse - Who Leads and Who Accelerates
  • North America
  • Asia-Pacific
  • Europe
  • LATAM and MEA
  • Five Strategy Headlines to Internalize
  • Structural Shifts by Modality, Application, Pathway and End Use
  • Competitive Architecture and Vendor Clusters
  • Three-Year KPI Outlook and Board-Level Actions
  • Actions for Vendors Over the Next 12 Months
Section 2 Research Methodology
  • About This Report
  • Scope and Segmentation
  • Segmentation Axes
  • Dual-Lens Architecture
  • Top-Down Market Funnel
  • Bottom-Up Attach-Rate Flow
  • Evidence Confidence
  • Framework Stack
  • Company Coverage, GTM Growth-Maturity and Competitive Datasets
  • Company Universe and Clustering
  • GTM Growth-Maturity Quadrants
  • Competitive Dataset Tables
  • Evidence Confidence
  • Upgrade and Package Ladders
  • Definitions
  • Default Commercial Rules
  • Cluster-Based Competitive Architecture and Market Segment Bridging
  • Quality Assurance, Limitations and Scenario Handling
Section 3 Strategic Analysis and Frameworks
  • AI Software Cluster
  • Market Momentum Matrix (AI Software)
  • ARC Framework - Oncology Use Cases
  • ARC Grid - AI Software
  • ARC Index
  • Upgrade Ladder Mapping
  • Recommendations for AI Software Vendors
  • GTM Growth-Maturity Matrix - AI Software Vendors
  • Competitive Dataset - AI Software
  • Company Scoreboard
  • Market Segmentation Bridge
  • Upgrade and Package Ladder
  • Target Customers and Package Composition
  • Recommended Commercial Rules
  • Company Spotlights - AI Software Vendors
  • Imaging OEMs Cluster
  • ARC Framework - OEM Use Cases
  • ARC Grid - OEMs
  • Competitive Dataset - OEMs
  • Scoreboard - OEMs
  • Upgrade and Package Ladder - OEMs
  • Company Spotlights - OEMs
  • RT and Oncology Planning Cluster
  • Market Momentum Matrix - RT
  • ARC Framework - RT
  • Recommendations
  • GTM Growth-Maturity Matrix - RT Vendors
  • Cluster Bridge and Upgrade Ladder
  • Company Spotlights - RT Vendors
  • AI Platforms and Cloud Cluster
  • ARC Framework - Platforms and Cloud
  • Market Momentum Matrix
  • Competitive Dataset and Scoreboard
  • Upgrade and Package Ladder
  • Company Spotlights - Platform Vendors
  • Providers and Teleradiology Cluster
  • Market Momentum Matrix
  • ARC Framework - Providers
  • Competitive Dataset and Scoreboard
  • Upgrade and Package Ladder
  • Company Spotlights - Providers
  • Imaging-Pharma and CRO Cluster
  • Market Momentum Matrix
  • ARC Framework
  • Competitive Dataset and Scoreboard
  • Upgrade and Package Ladder
  • Company Spotlights
Section 4 World Market for Oncology Imaging AI
  • Market Overview
  • Adoption Drivers
  • Regional Growth Snapshot
  • Strategic Implications
  • Market Momentum and Outlook
  • Forecast by Region
  • Market by Country × End Use
  • Market by Modality
  • Modality Deep Dives
  • Market by Clinical Application
  • Application Deep Dives
  • Market by Tumor Site
  • Tumor Site Deep Dives
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
  • Regional Mix and Momentum
  • Disease-Driven Demand Map
  • Workflow Economics
  • Pathway Stage Economics
Section 5 North America
  • Market Overview
  • Differences to Plan Around
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 6 United States
  • Market Overview and Dynamics
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 7 Canada
  • Market Overview and Dynamics
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 8 Europe
  • Market Overview and Dynamics
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 9 Germany
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 10 France
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 11 United Kingdom
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 12 Italy
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 13 Rest of Europe
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 14 Asia-Pacific
  • Regional Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 15 China
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 16 Japan
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 17 India
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
Section 18 Rest of Asia-Pacific
  • Market Overview
  • Market by Modality
  • Market by Clinical Application
  • Market by Tumor Site
  • Market by Revenue Stream
  • Market by End-Use Organization
  • Market by AI Technology
  • Market by Pathway Stage
List of Tables
Table 1: World Market for AI in Oncology Imaging by Region (2023-2032, USD Million)
Table 2: World Market for Oncology Imaging AI by Country x End-Use Org (2023)
Table 3: World Market for Oncology Imaging AI by Country x End-Use Org (2032)
Table 4: World Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 5: World Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 6: World Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 7: World Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 8: World Market for Oncology Imaging AI by End-Use Org (USD Mill, 2023-32)
Table 9: World Market for Oncology Imaging AI by Technology (USD Mill, 2023-32)
Table 10: World Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 11: World Market for Oncology Imaging AI by Region x Modality (USD Mill, 2023)
Table 12: World Market for Oncology Imaging AI by Region x Modality (USD Mill, 2032)
Table 13: World Market for Oncology Imaging AI by Region x Revenue Stream (USD Mill, 2023)
Table 14: World Market for Oncology Imaging AI by Region x Revenue Stream (USD Mill, 2032)
Table 15: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2023)
Table 16: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2032)
Table 17: World Market for Oncology Imaging AI by Tumor Site x Modality (USD Mill, 2023)
Table 18: World Market for Oncology Imaging AI by Tumor Site x Modality (USD Mill, 2032)
Table 19: World Market for Oncology Imaging AI by Tumor Site x Clinical Application (USD Mill, 2023)215
Table 20: World Market for Oncology Imaging AI by Tumor Site x Clinical Application (USD Mill, 2032)215
Table 21: World Market for Oncology Imaging AI by Tumor Site x Revenue Stream (USD Mill, 2023) 218
Table 22: World Market for Oncology Imaging AI by Tumor Site x Revenue Stream (USD Mill, 2032)
Table 23: World Market for Oncology Imaging AI by Modality x Revenue Stream (2023)
Table 24: World Market for Oncology Imaging AI by Modality X Revenue Stream (2032)
Table 25: World Market for Oncology Imaging AI by Clinical Application x Revenue Stream (2023)
Table 26: World Market for Oncology Imaging AI by Clinical Application x Revenue Stream (2032)
Table 27: World Market for Oncology Imaging AI - By Pathway Stage X Revenue Stream (USD Mill, 2023)
Table 28: World Market for Oncology Imaging AI - By Pathway Stage X Revenue Stream (USD Mill, 2032)
Table 29: World Market for Oncology Imaging AI - By Pathway Stage X Modality (USD Mill, 2023)
Table 30: World Market for Oncology Imaging AI - By Pathway Stage X Modality (USD Mill, 2032)
Table 31: World Market for Oncology Imaging AI by Pathway Stage x Clinical Application (USD Mill, 2023)
Table 32: World Market for Oncology Imaging AI by Pathway Stage x Clinical Application (USD Mill, 2032)
Table 33: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (USD Mill, 2023)
Table 34: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (USD Mill, 2032)
Table 35: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2023) . 245
Table 36: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2032) . 245
Table 37: North American Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 38: North American Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32) 258
Table 39: North American Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 40: North American Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 41: North American Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 42: North American Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 43: North America Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 44: United States Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 45: United States Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 46: United States Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 47: United States Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 48: United States Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 49: United States Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 50: United States Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 51: Canadian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 52: Canadian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 53: Canadian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 54: Canadian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 55: Canadian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 56: Canadian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 57: Canadian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 58: European Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 59: European Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 60: European Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 61: European Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 62: European Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 63: European Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 64: European Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 65: German Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 66: German Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 67: German Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 68: German Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 69: German Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 70: German Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 71: German Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 72: French Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 73: French Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 74: French Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 75: French Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 76: French Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 77: French Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 78: French Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 79: UK Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 80: UK Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 81: UK Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 82: UK Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 83: UK Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 84: UK Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 85: UK Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 86: Italian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 87: Italian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 88: Italian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 89: Italian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 90: Italian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 91: Italian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 92: Italian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 93: Rest of European (ROE) Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 94: Rest of European (ROE) Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 95: Rest of European (ROE) Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32). 455
Table 96: Rest of European (ROE) Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 97: Rest of European (ROE) Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 98: Rest of European (ROE) Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 99: Rest of European (ROE) Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 100: APAC Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 101: APAC Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 102: APAC Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 103: APAC Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 104: APAC Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 105 APAC Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 106: Chinese Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 107: Chinese Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 108: Chinese Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 109: Chinese Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 110: Chinese Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 111: Chinese Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 112: Chinese Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 113: Japanese Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 114: Japanese Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 115: Japanese Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 116: Japanese Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 117: Japanese Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 118: Japanese Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 119: Japanese Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 120: Indian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 121: Indian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 122: Indian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 123: Indian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 124: Indian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 125: Indian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 126: Indian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 127: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 128: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 129: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 130: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 131: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 132: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 133: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 134: LATAM Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 135: MEA Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 136: MEA Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 137: MEA Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 138: MEA Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 139: MEA Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 140: MEA Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 141: MEA Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)

List of Figures
Figure 1: World Oncology Imaging AI Market by Pathway Stage - 2023 vs 2032
Figure 2: Oncology Imaging AI - Global Drivers & Restraints
Figure 3: Oncology Imaging AI Market by Region - 2032 Revenue and 2023-2032 CAGR
Figure 4: Oncology Imaging AI Market by Modality - 2023 vs 2032
Figure 5: Oncology Imaging AI Market by Clinical Application - 2023 vs 2032
Figure 6: Oncology Imaging AI - Competitive Cluster Architecture
Figure 7: Oncology Imaging AI - Segmentation Compass (Full Taxonomy)
Figure 8: Oncology Imaging AI - Dual-Lens Forecast Build
Figure 9: Oncology Imaging AI - From Signals to Strategy
Figure 10: M³ - Market Momentum Matrix (AI Software Key Sub-Segments)
Figure 11: ARC Grid - AI Software - Oncology Imaging AI
Figure 12: GTM Growth vs. Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
Figure 13: Upgrade & Package Ladder - AI Software - Oncology Imaging AI
Figure 14: M³ - Market Momentum Matrix (Imaging OEMs)
Figure 15: ARC Grid - Imaging OEMs - Oncology Imaging AI
Figure 16: GTM Growth vs. Maturity Matrix - Imaging OEM Vendors (Oncology Imaging AI) 112
Figure 17: Upgrade & Package Ladder - Imaging OEM Cluster - Oncology Imaging AI
Figure 18: M³ - Market Momentum Matrix - RT/Oncology Planning (Oncology Imaging AI)
Figure 19: ARC Grid - RT/Oncology Planning - Oncology Imaging AI
Figure 20: GTM Growth vs. Maturity Matrix - RT/Oncology Planning (Oncology Imaging AI) 123
Figure 21: Upgrade & Package Ladder - RT/Oncology Planning Cluster - Oncology Imaging AI
Figure 22: M³ - Market Momentum Matrix (AI Platform & Cloud Sub-segment)
Figure 23: ARC Grid - AI Platforms & Cloud - Oncology Imaging AI
Figure 24: GTM Growth vs. Maturity Matrix - AI Platforms and Cloud (Oncology Imaging AI)
Figure 25: Upgrade & Package Ladder - AI Platforms & Cloud - Oncology Imaging AI
Figure 26: M³ - Market Momentum Matrix (AI Providers & Teleradiology Sub-Segment)
Figure 27: ARC Grid - Providers & Teleradiology - Oncology Imaging AI
Figure 28: GTM Growth vs. Maturity Matrix - Providers & Teleradiology (Oncology Imaging AI)
Figure 29: Upgrade & Package Ladder - Providers & Teleradiology Cluster - Oncology Imaging AI
Figure 30: M³ - Market Momentum Matrix (Imaging-Pharma/CRO & Trials Key Sub-Segment)
Figure 31: ARC Grid - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
Figure 32: GTM Growth vs. Maturity Matrix - Imaging-Pharma / CRO & Trials (Oncology Imaging AI)
Figure 33: Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
Figure 34: Global Oncology Imaging AI - Country x End-Use Org (2032 Market Size and Index vs. Global Mix)
Figure 35: Global Oncology Imaging AI - Country x End-Use (Dollar Lift 2023 to 2032)
Figure 36: Global Oncology Imaging AI Market by Modality: 2023 vs. 2032
Figure 37: Global Oncology Imaging AI Growth Contribution by Modality: Dollar Lift 2023 to 2032
Figure 38: Global Oncology Imaging AI Market by Clinical Application: 2023 vs. 2032
Figure 39: Global Oncology Imaging AI Growth Contribution by Clinical Application: Dollar Lift 2023 to 2032
Figure 40: Global Oncology Imaging AI Growth Contribution by Tumor Site: Dollar Lift 2023 to 2032
Figure 41: Global Oncology Imaging AI Growth Contribution by Tumor Site: Dollar Lift 2023 to 2032
Figure 42: Global Oncology Imaging Growth Contribution by Revenue Stream: Dollar Lift 2023 to 2032
Figure 43: Global Oncology Imaging Market by End-Use Org: 2023 vs. 2032
Figure 44: Global Oncology Imaging Growth Contribution by End-Use Org: Dollar Lift 2023 to 2032
Figure 45: Global Oncology Imaging Market by AI Technology: 2023 vs. 2032
Figure 46: World Market for Oncology Imaging AI by Technology (USD Mill, 2023-32)
Figure 47: Global Oncology Imaging Market by Pathway Stage: 2023 vs. 2032
Figure 48: Global Oncology Imaging AI Growth Contribution by Pathway Stage: Dollar Lift 2023 to 2032
Figure 49: Global Oncology Imaging AI - Region x Modality (2032 Market Size and Index vs. Global Mix)
Figure 50: Global Oncology Imaging AI - Region x Modality (Dollar Lift 2023 vs 2032)
Figure 51: Global Oncology Imaging AI - Region x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 52: Global Oncology Imaging AI - Region x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 53: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2032)
Figure 54: Global Oncology Imaging AI - Region x Clinical Application (Dollar Lift 2023 to 2032)
Figure 55: Global Oncology Imaging AI - Tumor Site x Modality (2032 Market Size and Index vs. Global Mix)
Figure 56: Global Oncology Imaging AI - Tumor Site x Modality (Dollar Lift 2023 to 2032)
Figure 57: Global Oncology Imaging AI - Tumor Site x Clinical Application (2032 Market Size and Index vs. Global Mix)
Figure 58: Global Oncology Imaging AI - Tumor Site x Clinical Application (Dollar Lift 2023 to 2032)
Figure 59: Global Oncology Imaging AI - Tumor Site x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 60: Global Oncology Imaging AI - Tumor Site x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 61: Global Oncology Imaging AI - Modality x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 62: Global Oncology Imaging AI - Modality x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 63: Global Oncology Imaging AI - Clinical Application x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 64: Global Oncology Imaging AI - Clinical Application x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 65: Global Oncology Imaging AI - Pathway Stage x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 66: Global Oncology Imaging AI - Pathway Stage x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 67: Global Oncology Imaging AI - Pathway Stage x Modality (2032 Market Size and Index vs. Global Mix)
Figure 68: Global Oncology Imaging AI - Pathway Stage x Modality (2032 Market Size and Index vs. Global Mix)
Figure 69: Global Oncology Imaging AI - Pathway Stage x Clinical Application (2032 Market Size and Index vs. Global Mix)
Figure 70: Global Oncology Imaging AI - Pathway Stage x Clinical Application (Dollar Lift 2023 to 2032)
Figure 71: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (2032 Market Size and Index vs. Global Mix)
Figure 72: Global Oncology Imaging AI - Pathway Stage x End-Use (Dollar Lift 2023 to 2032)
Figure 73: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (2032 Over/Under Mix)
Figure 74: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2032) 247
Figure 75: North America - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 76: North America - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 77: North America - Country x Modality Dollar Lift, 2023 to 2032
Figure 78: North America - Clinical Application Dollar-Lift, (2023-2032) [US$M]
Figure 79: North America - Country x Clinical Application Dollar Lift, 2023 to 2032
Figure 80: North America - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 81: North America - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 82: North America - Country x Tumor Site Dollar Lift, 2023 to 2032
Figure 83: North America - Tumor Site vs Scale (Bubble = Dollar Lift)
Figure 84: North America - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 85: North America - Dollar Lift (from 2023 - 2032) by Revenue Stream (US vs Canada)
Figure 86: North America - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 87: North America - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 88: North America - Dollar Lift (from 2023 - 2032) by End-Use Org (US vs Canada)
Figure 89: North America - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 90: North America - Dollar Lift (from 2023 - 2032) by AI Technology (US vs Canada)
Figure 91: North America - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 92: North America - Dollar Lift (from 2023 - 2032) by Pathway Stage (US vs Canada)
Figure 93: United States - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 94: United States - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 95: United States - Modality Mix Shift (from 2023 to 2032) (Share Arrows)
Figure 96: United States - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 97: United States - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 98: United States - Clinical Application Shift (from 2023 to 2032) (Share Arrows)
Figure 99: United States - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 100: United States - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 101: United States - Tumor Site Mix Shift (from 2023 to 2032) (Share Arrows)
Figure 102: United States - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 103: United States - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 104: United States - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 105: United States - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 106: United States - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 107: United States - AI technology Growth vs Scale (Bubble = Dollar Lift)
Figure 108: United States - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 109: United States - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 110: Canada - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 111: Canada - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 112: Canada - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 113: Canada - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 114: Canada - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 115: Canada - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 116: Canada - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 117: Canada - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 118: Canada - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 119: Canada - End-Use Org Mix Shift, 2023 to 2032 (Share Arrows)
Figure 120: Canada - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 121: Canada - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 122: Canada - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 123: Canada - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 124: Canada - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 125: Canada - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 126: Europe - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 127: Europe - Dollar Lift ’23-’32 by Modality (Stacked by Country)
Figure 128: Europe - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 129: Europe - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 130: Europe - Dollar Life ’23-’32 by Clinical Application (Stacked by Country)
Figure 131: Europe - Clinical Application - Growth vs Scale (Bubble = Dollar Lift)
Figure 132: Europe - Tumor Sites Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 133: Europe - Dollar Life ’23-’32 by Tumor Site (Stacked by Country)
Figure 134: Europe - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 135: Europe - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 136: Europe - Dollar Lift ’23-’32 by Revenue Stream (Stacked by Country)
Figure 137: Europe - Dollar-Lift Contribution, End-User Orgs, 2023 to 2032 (Waterfall)
Figure 138: Europe - Dollar Lift ’23-’32 by End-Use Org (Stacked by Country)
Figure 139: Europe - AI technologies Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 140: Europe - Dollar Lift ’23-’32 by AI Technology (Stacked by Country)
Figure 141: Europe - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 142: Europe -Dollar Lift ’23-’32 by Pathway Stage (Stacked by Country)
Figure 143: Germany - Modality Slope (Oncology Imaging AI), 2023-2032
Figure 144: Germany - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 145: Germany - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 146: Germany - Clinical Application Mix Shift, 2023 to 2032 (Share Arrows)
Figure 147: Germany - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 148: Germany - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 149: Germany - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 150: Germany - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 151: Germany - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 152: Germany - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 153: Germany - End-Use Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 154: Germany - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 155: Germany - End-Use Orgs Mix Shift, 2023 to 2032 (Share Arrows)
Figure 156: Germany - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 157: Germany - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 158: Germany - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 159: Germany - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 160: Germany - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 161: Germany - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 162: France - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 163: France - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 164: France - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 165: France - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 166: France - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 167: France - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 168: France - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 169: France - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 170: France - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 171: France - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 172: France - End-Use Orgs Mix Shift, 2023 to 2032 (Share Arrows)
Figure 173: France - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 174: France - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 175: France - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 176: France - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 177: UK - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 178: UK - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 179: UK - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 180: UK - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 181: UK - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 182: UK - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 183: UK - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 184: UK - Revenue Streams Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 185: UK - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 186:UK - End-Use Mix Shift, 2023 to 2032 (Share Arrows)
Figure 187: UK - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 188: UK - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 189: UK - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 190: UK - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 191: UK - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 192: UK - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 193: UK - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 194: Italy - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 195: Italy - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 196: Italy - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 197: Italy - Clinical Applications Growth vs Scale (Bubble = Dollar Lift)
Figure 198: Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 199: Italy - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 200: Italy - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 201: Italy - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 202: Italy - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 203: Italy - End-use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 204: Italy - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 205: Italy - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 206: Italy - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 207: Italy - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 208: Rest of Europe - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 209: Rest of Europe - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 210: Rest of Europe - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 211: Growth vs Scale (Bubble = Dollar Lift)
Figure 212: Rest of Europe - Clinical Application Mix Shift, 2023 to 2032 (Share Arrows)
Figure 213: Rest of Europe - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 214: Rest of Europe - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 215: Rest of Europe - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 216: Rest of Europe - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 217: Rest of Europe - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 218: Rest of Europe - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 219: Rest of Europe - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 220: Rest of Europe - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 221: Rest of Europe - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 222: Rest of Europe - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 223: APAC - Modalities Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 224: APAC - Dollar Lift ’23-’32 by Tumor Site (Stacked by Country)
Figure 225: APAC - Clinical Applications Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 226: APAC - Dollar Lift ’23-’32 by Clinical Application (Stacked by Country)
Figure 227: APAC - Tumor Sites Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 228: APAC - Tumor Sites Dollar Lift ’23-’32 by Tumor Site (Stacked by Country)
Figure 229: APAC - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 230: APAC - Revenue Streams Dollar Lift ’23-’32 by Tumor Site (Stacked by Country)
Figure 231: APAC - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 232: End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 233: APAC - AI Technologies Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 234: APAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 235: APAC - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 236: APAC - Dollar Lift ’23-’32 by Pathway Stage (Stacked by Country)
Figure 237: China - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 238: China - Modality Mix Shift, 2023 to 2032 (Share Arrows)
Figure 239: China - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 240: China - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 241: China - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 242: China - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 243: China - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 244: China - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 245: China - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 246: China - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 247: China - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 248: Growth vs Scale (Bubble = Dollar Lift)
Figure 249: China - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 250: China - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 251: China - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 252: China - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 253: China - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 254: Japan - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 255: Japan - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 256: Japan - Clinical Application Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 257: Japan - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 258: Japan - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 259: Japan - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 260: Japan - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 261: Japan - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 262: Japan - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 263: Japan - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 264: Japan - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 265: Japan - End-Use Mix Shift, 2023 to 2032 (Share Arrows)
Figure 266: Japan - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 267: Japan - End-Use Org Mix Shift, 2023 to 2032 (Share Arrows)
Figure 268: Japan - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 269: Japan - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 270: Mix Shift, 2023 to 2032 (Share Arrows)
Figure 271: Japan - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 272: India - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 273: India - Modality Mix Shift, 2023 to 2032 (Share Arrows)
Figure 274: India - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 275: India - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 276: India - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 277: India - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 278: India - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 279: India - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 280: India - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 281: India - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 282: Growth vs Scale (Bubble = Dollar Lift)
Figure 283: India - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 284: India - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 285: India - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 286: India - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 287: India - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 288: ROAPAC - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 289: ROAPAC - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 290: ROAPAC - Clinical Application Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 291: ROAPAC - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 292: ROAPAC - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 293: ROAPAC - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 294: ROAPAC - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 295: ROAPAC - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 296: ROAPAC - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 297: ROAPAC - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 298: ROAPAC - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 299: ROAPAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 300: ROAPAC - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 301: ROAPAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 302: ROAPAC - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 303: LATAM Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Figure 304: Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 305: LATAM - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 306: LATAM Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Figure 307: LATAM - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 308: LATAM - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 309: LATAM Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Figure 310: LATAM - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 311: LATAM - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 312: LATAM Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Figure 313: LATAM - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 314: LATAM - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 315: LATAM Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Figure 316: LATAM - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 317: Growth vs Scale (Bubble = Dollar Lift)
Figure 318: LATAM Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Figure 319: LATAM - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 320: LATAM - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 322: LATAM - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 323: Growth vs Scale (Bubble = Dollar Lift)
Figure 325: MEA - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 326: MEA - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 328: MEA - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 329: MEA - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 331: MEA - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 332: MEA - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 334: MEA - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 335: MEA - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 337: MEA - End-Use Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 338: MEA - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 340: MEA - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 341: MEA - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 343: MEA - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 344: MEA - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)

Companies Mentioned

  • 5C Network
  • Accuray
  • Aidoc
  • AIQ Solutions
  • Bracco
  • Brainlab
  • Canon Medical
  • CARPL.ai
  • deepc (deepcOS)
  • DocPanel
  • Elekta
  • Everlight Radiology
  • Ferrum Health
  • Fujifilm Healthcare
  • GE HealthCare
  • Guerbet
  • Hologic
  • Incepto
  • Koios Medical
  • Lantheus / EXINI (aPROMISE / PYLARIFY AI)
  • Limbus AI
  • Lunit
  • Median Technologies
  • MIM Software
  • Mirada Medical
  • MVision AI
  • Nuance Precision Imaging Network (PIN)
  • Philips Healthcare
  • Quibim;
  • QView Medical
  • RadNet / DeepHealth
  • RaySearch Laboratories
  • Riverain Technologies
  • Samsung Healthcare
  • ScreenPoint Medical (Transpara)
  • Siemens Healthineers
  • Teleradiology Solutions
  • Tempus (Arterys)
  • Therapixel (MammoScreen)
  • Unilabs / Telemedicine Clinic (TMC)
  • United Imaging
  • Vara
  • vRad

Related Topics

Related Reports

World Market for AI in Medical Imaging 2025-2032 - Product Image

World Market for AI in Medical Imaging 2025-2032

  • Report
  • 893 Pages
  • Global
From
Europe AI-assisted Medical Imaging Market 2025-2032 - Product Image

Europe AI-assisted Medical Imaging Market 2025-2032

  • Report
  • Europe
From
Asia-Pacific AI-assisted Imaging Market 2025-2032 - Product Image

Asia-Pacific AI-assisted Imaging Market 2025-2032

  • Report
  • Asia Pacific
From
Latin America AI-assisted Imaging Market 2025-2032 - Product Image

Latin America AI-assisted Imaging Market 2025-2032

  • Report
  • Latin America
From
Middle East & Africa AI-assisted Medical Imaging Market 2025-2032 - Product Image

Middle East & Africa AI-assisted Medical Imaging Market 2025-2032

  • Report
  • Africa, Middle East
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.